Statins and cerebrovascular disease: plaque attack to prevent brain attack

Abstract

Stroke is the third leading cause of death in the USA and in the developed world. The beneficial role of cholesterol reduction in decreasing stroke has been uncertain. However, recent data indicate that statin treatment in patients with a history of myocardial infarction not only reduces the risk of a second myocardial infarction, coronary heart disease, revascularization procedures and death, but also significantly reduces the risk of stroke. However, the mechanism(s) by which statins reduce stroke remain uncertain. Thus, the therapeutic armamentarium for the reduction of stroke in secondary prevention now includes cholesterol reduction with statins.

Keywords

cholesterol statins stroke

References

Sacco RL. Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology 1997; 49: S39-S44.

Sacco RL , Kargman DE , Gu Q , Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995; 26: 14-20.

Silvestry FE , Tarka EA , Mohler ER. Echocardiographic and vascular ultrasound evaluation of cerebrovascular ischemic events. ACC Curr J Rev 1998; 6: 79-81.

Iso H , Jacobs DRJ , Wentworth D , Neaton JD , Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-910.

Benfante R , Yano K , Hwang LJ , Curb JD , Kagan A , Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 1994; 25: 814-820.

Wolf PA , Kannel WB , Verter J. Current status of risk factors for stroke. Neurol Clin 1983; 1: 317-343.

Heyman A , Karp HR , Heyden S et al. Cerebrovascular disease in the bi-racial population of Evans County, Georgia. Stroke 1971; 2: 509-518.

Salonen JT , Puska P , Tuomilehto J , Homan K. Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. A longitudinal study in Eastern Finland. Stroke 1982; 13: 327-333.

Tanaka H , Ueda Y , Hayashi M et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982; 13: 62-73.

10.

Prospective Studies Collaboration . Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-1653.

11.

Reed D , Yano K , Kagan A. Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer inthe Honolulu Heart Program. Am J Med 1986; 80: 871-878.

12.

O’Leary DH , Polak JF , Kronmal RA et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke 1996; 27: 224-231.

13.

O’Leary DH , Polak JF , Kronmal RA , Manolio TA , Burke GL , Wolf-son SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.

14.

Furberg CD , Adams HPJ , Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-1687.

15.

Crouse JR , Byington RP , Bond MG et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455-459.

16.

Salonen R , Nyyssonen K , Porkkala E et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-1764.

17.

Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.

18.

Pedersen TR , Kjekshus J , Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81: 333-335.

19.

Sacks FM , Pfeffer MA , Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.

20.

Plehn JF , Davis BR , Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (CARE) study. Circulation 1999; 99: 216-223.

21.

The long-term intervention with pravastatin in ischemic disease (LIPID) study group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.

22.

Shepherd J , Cobbe SM , Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.

23.

Blauw GJ , Lagaay AM , Smelt AH , Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946-950.

24.

Crouse JR , Byington RP , Hoen HM , Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157: 1305-1310.

25.

Vaughan CJ , Murphy MB , Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.

26.

Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.

27.

Delanty N , Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28: 2315-2320.

28.

Rohde E , Lee RT , Rivero J et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18: 1765-1770.

29.

The National Institute of Neurologic Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med 1995; 333: 1581-1587.

30.

Chen L , Haught WH , Yang B , Saldeen TG , Parathasarathy S , Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30: 569-575.

31.

Aviram M , Rosenblat M , Bisgaier CL , Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-280.

32.

O’Driscoll G , Green D , Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131.

33.

Endres M , Laufs U , Huang Z et al. Stroke protection by 3-hydroxy- 3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-8885.

34.

Lefer A , Campbell B , Shin YK , Scalia R. Simvastatin protects the ischemic reperfused myocardium from leukocyte-endothelium interaction and neutrophil induced cardiac dysfunction. Circulation 1998; 98: I-114-I-114 (Abstract).

35.

Gorelick PB , Sacco RL , Smith DB et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281: 1112-1120.